SCHEMBL20928583

SCHEMBL20928583

Cc1cc(-c2ccc(F)cc2C(C)C)n[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 4/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ PDE10A Q9Y233 1/20 0.41
▸ ALK Q9UM73 4/20 0.40
▸ NTRK1 P04629 1/20 0.40
▸ RAB9A P51151 3/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ ALPL P05186 2/20 0.39
▸ MEN1 O00255 2/20 0.37
▸ ALOX15 P16050 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ HCAR2 Q8TDS4 1/20 0.36
▸ SYK P43405 2/20 0.35
▸ AURKA O14965 1/20 0.35
▸ AURKB Q96GD4 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ NFKB1 P19838 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27942630 0.79 NPC1 (0.49) NPC1KDM4EGAAHSD17B10L3MBTL1
SCHEMBL22415326 0.74 HPGD (0.50) NPC1KDM4EGAAHSD17B10L3MBTL1
SCHEMBL8226904 0.72 NPC1 (0.50) NPC1KDM4EGAAHSD17B10L3MBTL1
SCHEMBL20928591 0.71 HTT (0.39) NPC1KDM4EGAARAB9AMEN1
SCHEMBL2360295 0.71 NPC1 (0.67) NPC1L3MBTL1ALKRAB9ASMN1; SMN2
SCHEMBL22479888 0.70 SCN4A (0.43) NTRK1KMT2A
SCHEMBL20928596 0.70 SMN1; SMN2 (0.42) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL13351413 0.70 MAPK1 (0.39) NPC1HSD17B10NTRK1RAB9ASMN1; SMN2
SCHEMBL27021630 0.69 GPR35 (0.45) NPC1KDM4EGAAHSD17B10L3MBTL1
SCHEMBL22055438 0.68 NPC1 (0.64) NPC1KDM4EGAAHSD17B10L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11022880-B2 Chemically amplified positive-type photosensitive resin composition, photosensitive dry film, method of manufacturing photosensitive dry film, method of manufacturing patterned resist film, method of manufacturing substrate with template, method of manufacturing plated article, and mercapto compound TOKYO OHKA KOGYO CO., LTD. (JP) 2021-06-01 — — US disclosed
US-20190121233-A1 CHEMICALLY AMPLIFIED POSITIVE-TYPE PHOTOSENSITIVE RESIN COMPOSITION, PHOTOSENSITIVE DRY FILM, METHOD OF MANUFACTURING PHOTOSENSITIVE DRY FILM, METHOD OF MANUFACTURING PATTERNED RESIST FILM, METHOD OF MANUFACTURING SUBSTRATE WITH TEMPLATE, METHOD OF MANUFACTURING PLATED ARTICLE, AND MERCAPTO COMPOUND TOKYO OHKA KOGYO CO., LTD. (JP) 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190121233-A1 CHEMICALLY AMPLIFIED POSITIVE-TYPE PHOTOSENSITIVE RESIN COMPOSITION, PHOTOSENSITIVE DRY FILM, METHOD OF MANUFACTURING PHOTOSENSITIVE DRY FILM, METHOD OF MANUFACTURING PATTERNED RESIST FILM, METHOD OF MANUFACTURING SUBSTRATE WITH TEMPLATE, METHOD OF MANUFACTURING PLATED ARTICLE, AND MERCAPTO COMPOUND CUTA, POLR1C, ASIC1 NPC1 4878/4885KDM4E 2101/4885GAA 2837/4885
US-11022880-B2 Chemically amplified positive-type photosensitive resin composition, photosensitive dry film, method of manufacturing photosensitive dry film, method of manufacturing patterned resist film, method of manufacturing substrate with template, method of manufacturing plated article, and mercapto compound CUTA, POLR1C, ASIC1 NPC1 4878/4885KDM4E 2101/4885GAA 2837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback